
|Videos|April 7, 2016
Jay Edelberg from Sanofi: Praluent Continues to Show Benefits Since Approval
Author(s)Adam Hochron
At the 2015 meeting of the American College of Cardiology PCSK9 inhibitors like Praluent were moving closer to approval but were not there yet. Since then they have been approved and begun to be introduced to the public.
Advertisement
At the 2015 meeting of the American College of Cardiology (ACC) PCSK9 inhibitors like Praluent were moving closer to approval but were not there yet. Since then they have been approved and begun to be introduced to the public.
Jay Edelberg, MD, PhD, from Sanofi discussed how things have changed for the medication over the course of the year and what the future is during the 2016 meeting of the ACC in Chicago.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
High-Dose Semaglutide Preserves Kidney Function, Reduces Inflammation in Obesity Without Diabetes
4
Berobenatide Monthly Dosing Shows Weight Loss Efficacy in VESPER Trials, With John Buse, MD, PhD
5


























































